Prevention of radiation-induced central nervous system toxicity: A role for amifostine?

Anticancer Research

Volumn 24, Issue 6, 2004, Pages 3803-3809

  Nieder, Carsten ^a   Andratschke, Nicolaus H ^a   Wiedenmann, Nicole ^a   Molls, Michael ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Amifostine; Brain; Central nervous system; Radiation therapy; Spinal cord

Indexed keywords

2 (3 AMINOPROPYLAMINO)ETHANETHIOL; AMIFOSTINE; CISPLATIN; GRANULOCYTE COLONY STIMULATING FACTOR; RADIOPROTECTIVE AGENT;

BLOOD BRAIN BARRIER; BLOOD VESSEL INJURY; BRAIN RADIATION; CELL MEMBRANE PERMEABILITY; DOSE RESPONSE; DRUG EFFICACY; FOLLOW UP; HUMAN; IN VIVO STUDY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; RADIATION INJURY; REVIEW; SPINAL CORD; ANIMAL; BRAIN; CENTRAL NERVOUS SYSTEM DISEASE; RADIATION EXPOSURE; RAT;

AMIFOSTINE; ANIMALS; BRAIN; CENTRAL NERVOUS SYSTEM DISEASES; HUMANS; RADIATION INJURIES, EXPERIMENTAL; RADIATION-PROTECTIVE AGENTS; RATS; SPINAL CORD;

EID: 14944385417     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Ang KK, van der Kogel AJ, Van Dam J et al: The kinetics of repair of sublethal damage in the rat cervical spinal cord during fractionated irradiations. Radiother Oncol 1: 247-253, 1984.
2. van der Schueren E, Landuyt W and Ang KK: From 2 Gy to 1 Gy per fraction: sparing effect in rat spinal cord? Int J Radiat Oncol Biol Phys 14: 297-300, 1988.
3. Ruifrok AC, Kleiboer BJ and van der Kogel AJ: Fractionation sensitivity of the rat cervical spinal cord during radiation retreatment. Radiother Oncol 25: 295-300, 1992.
4. Wong CS, Minkin S and Hill RP: Re-irradiation tolerance of rat spinal cord to fractionated X-ray doses. Radiother Oncol 28: 197-202, 1993.
5. Wong CS and Hao Y: Long-term recovery kinetics of radiation damage in rat spinal cord. Int J Radiat Oncol Biol Phys 37: 171-179, 1997.
6. Ang KK, Jiang GL, Feng Y et al: Extent and kinetics of recovery of occult spinal cord injury. Int J Radiat Oncol Biol Phys 50: 1013-1020, 2001.
7. Lee EJ, Gerhold M, Palmer MW et al: p53 protein regulates the effects of amifostine on apoptosis, cell cycle progression, and cytoprotection. Br J Cancer 88: 754-759, 2003.
8. Antonadou D, Petridis A, Synodinou M et al: Amifostine reduces radiochemotherapy-induced toxicities in patients with locally advanced non-small cell lung cancer. Semin Oncol (Suppl 18): 2-9, 2003.
9. Brizel DM, Wasserman TH, Henke M et al: Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 18: 3339-45, 2000.
10. Bourhis J, De Crevoisier R, Abdulkarim B et al: A randomized study of very accelerated radiotherapy with and without amifostine in head and neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 46: 1105-8, 2000.
11. Komaki R, Lee JS, Milas L et al: Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial. Int J Radiat Oncol Biol Phys 58: 1369-1377, 2004.
12. Vacha P, Fehlauer F, Mahlmann B et al: Randomized phase III trial of postoperative radiochemotherapy +/-amifostine in head and neck cancer. Is there evidence for radioprotection? Strahlenther Onkol 179: 385-389, 2003.
13. Koukourakis MI, Kyrias G, Kakolyris S et al: Subcutaneous administration of amifostine during fractionated radiotherapy: a randomized phase II study. J Clin Oncol 19: 2226-2233, 2000.
14. Nieder C, Andratschke N, Price RE et al: Innovative prevention strategies for radiation necrosis of the central nervous system. Anticancer Res 22: 1017-1023, 2002.
15. Nieder C, Price RE, Rivera B et al: Experimental data on administration of insulin-like growth factor-1 and basic fibroblast growth factor for prevention of radiation myelopathy (German). Strahlenther Onkol 178: 147-152, 2002.
16. Andratschke NH, Nieder C, Price RE et al: Modulation of rodent spinal cord radiation tolerance by administration of platelet-derived growth factor. Int J Radiat Oncol Biol Phys 60: 1257-1263, 2004
17. Tofilon PJ and Fike JR: The radioresponse of the central nervous system: a dynamic process. Radiat Res 153: 357-370, 2000.
18. Guelman LR, Zorrilla Zubilete MA, Rios H et al: WR-2721 (amifostine, ethyol) prevents motor and morphological changes induced by neonatal X-irradiation. Neurochem Int 42: 385-391, 2003.
19. Alaoui F, Pratt J, Trocherie S et al: Acute effects of irradiation on the rat brain: protection by glutamate blockade. Eur J Pharmacol 276: 55-60, 1995.
20. Lamproglou I, Djazouli K, Boisserie G et al: Radiation-induced cognitive dysfunction: the protective effect of ethyol in young rats. Int J Radiat Oncol Biol Phys 57: 1109-1115, 2003.
21. Plotnikova ED, Levitman MK, Shaposhnikova VV et al: Protection of microvasculature in rat brain against late radiation injury by gammaphos. Int J Radiat Oncol Biol Phys 15: 1197-1201, 1988.
22. Plotnikova, ED, Levitman MK, Shaposhnikova W et al: Protection of microcirculation in rat brain against late radiation injury by gammaphos. Int J Radiat Oncol Biol Phys 10: 365-368, 1984.
23. Spence AM, Krohn KA, Edmondson SW et al: Radioprotection in rat spinal cord with WR-2721 following cerebral lateral intraventricular injection. Int J Radiat Oncol Biol Phys 12: 1479-1482, 1986.
24. Lamperti A, Conger AD, Jenkins O et al: WR-2721 entry into the brain across a modified blood-brain barrier. Radiat Res 115: 303-313, 1988.
25. Dorresteijn LD, Kappelle AC, Boogerd W et al: Increased risk of ischemic stroke after radiotherapy on the neck in patients younger than 60 years. J Clin Oncol 20: 282-8, 2002.
26. Cheng SW, Ting AC, Ho P et al: Accelerated progression of carotid stenosis in patients with previous external neck irradiation. J Vasc Surg 39: 409-415, 2004.
27. Lam WW, Leung SF, So NM et al: Incidence of carotid stenosis in nasopharyngeal carcinoma patients after radiotherapy. Cancer 92: 2357-2363, 2001.
28. Dubec JJ, Munk PL, Tsang V et al: Carotid artery stenosis in patients who have undergone radiation therapy for head and neck malignancy. Br J Radiol 71: 872-875, 1998.
29. Carmody BJ, Arora S, Avena R et al: Accelerated carotid artery disease after high-dose head and neck radiotherapy: is there a role for routine carotid duplex surveillance? J Vasc Surg 30: 1045-1051, 1999.
30. Kortmann RD, Timmermann B, Taylor RE et al: Current and future strategies in radiotherapy of childhood low-grade glioma of the brain. Part II: Treatment-related late toxicity. Strahlenther Onkol 779: 585-97, 2003.
31. Grdina DJ, Murley JS, Kataoka Y et al: Differential activation of nuclear transcription factor kappaB, gene expression, and proteins by amifostine's free thiol in human microvascular endothelial and glioma cells. Semin Radiat Oncol 12 (Suppl 1): 103-111, 2002.
32. Andreopoulos D, Schleicher LJM, Cotarelo CL et al: Radioprotection of human endothelial cells with amifostine. Strahlenther Onkol 175 (Suppl 4): 34-36, 1999.
33. Plasswilm L, Hanjalic A, Hoeper J et al: Microvessel density and endothelial cell proliferation after amifostine (Ethyol) administration in vivo. Anticancer Res 19: 4241-4245, 1999.
34. Giannopoulou E, Katsoris P, Parthymou A et al: Amifostine protects blood vessels from the effects of ionizing radiation. Anticancer Res 22: 2821-2826, 2002.
35. Kruse JJ, Strootman EG and Wondergem J: Effects of amifostine on radiation-induced cardiac damage. Acta Oncol 42: 4-9, 2003.
36. Kataoka Y, Murley JS, Patel R et al: Cytoprotection by WR-1065, the active form of amifostine, is independent of p53 status in human malignant glioma cell lines. Int J Radiat Biol 76: 633-639, 2000.
37. Bergstrom P, Johnsson A, Bergenheim T et al: Effects of amifostine on cisplatin induced DNA adduct formation and toxicity in malignant glioma and normal tissues in rat. J Neurooncol 42: 13-21, 1999.
38. Koukourakis MI: Amifostine: is there evidence of tumor protection? Semin Oncol 30 (Suppl 18): 18-30, 2003.
39. Brizel DM and Overgaard J: Does amifostine have a role in chemoradiation treatment? Lancet Oncol 4: 378-381, 2003.
40. Leong SS, Tan EH, Fong KW et al: Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small cell lung cancer. J Clin Oncol 21: 1767-1774, 2003.
41. Werner-Wasik M, Axelrod RS, Friedland DP et al: Preliminary report on reduction of esophagitis by amifostine in patients with non-small-cell lung cancer. Clin Lung Cancer 2: 284-289, 2001.
42. Staar S, Rudat V, Stuetzer H et al: Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy-results of a multicentric randomised German trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 50: 1161-71, 2001.
43. Giatromanolaki A, Sivridis E, Maltezos E et al: Down-regulation of intestinal-type alkaline phosphatase in the tumor vasculature and stroma provides a strong basis for explaining amifostine selectivity. Semin Oncol 29 (Suppl 19): 14-21, 2002.
44. Fike JR, Gobbel GT, Marton LJ et al: Radiation brain injury is reduced by the polyamine inhibitor alpha-difluoromethylornithine. Radiat Res 138: 99-106, 1994.
45. Kondziolka D, Mori Y, Martinez AJ et al: Beneficial effects of the radioprotectant 21-aminosteroid U-74389G in a radiosurgery rat malignant glioma model. Int J Radiat Oncol Biol Phys 44: 179-184, 1999.
46. Hornsey S, Myers R and Jenkinson T: The reduction of radiation damage to the spinal cord by post-irradiation administration of vasoactive drugs. Int J Radiat Oncol Biol Phys 18: 1437-1442, 1990.
47. Rezvani M, Birds DA, Hodges H et al: Modification of radiation myelopathy by the transplantation of neural stem cells in the rat. Radiat Res 156: 408-412, 2001.